A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer

Phase 1 Completed 18 enrolled Astellas Pharma Inc Agensys, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer. AGS-8M4 will be administered as an IV infusion until the disease worsens.

Timeline

Start: 2008-10
Primary completion: 2010-06
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AGS-8M4	Unknown	—	Intravenous

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer

Summary

Timeline

Drugs

Indications